Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/TLN1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TLN1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TLN1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TLN1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TLN1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TLN1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TLN1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TLN1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TLN1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
GO:01501159 | Cervix | CC | cell-substrate junction organization | 37/2311 | 101/18723 | 3.20e-10 | 4.46e-08 | 37 |
GO:00070448 | Cervix | CC | cell-substrate junction assembly | 34/2311 | 95/18723 | 3.35e-09 | 3.45e-07 | 34 |
GO:00452169 | Cervix | CC | cell-cell junction organization | 53/2311 | 200/18723 | 3.83e-08 | 2.53e-06 | 53 |
GO:00072295 | Cervix | CC | integrin-mediated signaling pathway | 34/2311 | 107/18723 | 1.01e-07 | 5.25e-06 | 34 |
GO:00343298 | Cervix | CC | cell junction assembly | 88/2311 | 420/18723 | 3.42e-07 | 1.38e-05 | 88 |
GO:00070439 | Cervix | CC | cell-cell junction assembly | 39/2311 | 146/18723 | 1.86e-06 | 5.94e-05 | 39 |
GO:005087810 | Cervix | CC | regulation of body fluid levels | 78/2311 | 379/18723 | 3.20e-06 | 8.77e-05 | 78 |
GO:003410910 | Cervix | CC | homotypic cell-cell adhesion | 26/2311 | 90/18723 | 2.12e-05 | 3.82e-04 | 26 |
GO:00308657 | Cervix | CC | cortical cytoskeleton organization | 19/2311 | 61/18723 | 8.72e-05 | 1.16e-03 | 19 |
GO:00705279 | Cervix | CC | platelet aggregation | 19/2311 | 67/18723 | 3.42e-04 | 3.58e-03 | 19 |
GO:00508176 | Cervix | CC | coagulation | 45/2311 | 222/18723 | 5.08e-04 | 4.94e-03 | 45 |
GO:00075966 | Cervix | CC | blood coagulation | 44/2311 | 217/18723 | 5.78e-04 | 5.52e-03 | 44 |
GO:00301682 | Cervix | CC | platelet activation | 28/2311 | 123/18723 | 8.92e-04 | 7.71e-03 | 28 |
GO:00075996 | Cervix | CC | hemostasis | 44/2311 | 222/18723 | 9.47e-04 | 7.95e-03 | 44 |
GO:00308667 | Cervix | CC | cortical actin cytoskeleton organization | 12/2311 | 40/18723 | 2.44e-03 | 1.71e-02 | 12 |
GO:000722913 | Cervix | HSIL_HPV | integrin-mediated signaling pathway | 19/737 | 107/18723 | 3.37e-08 | 2.76e-06 | 19 |
GO:004206015 | Cervix | HSIL_HPV | wound healing | 40/737 | 422/18723 | 2.80e-07 | 1.61e-05 | 40 |
GO:005087814 | Cervix | HSIL_HPV | regulation of body fluid levels | 37/737 | 379/18723 | 3.81e-07 | 2.06e-05 | 37 |
GO:004521614 | Cervix | HSIL_HPV | cell-cell junction organization | 23/737 | 200/18723 | 4.21e-06 | 1.69e-04 | 23 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TLN1 | SNV | Missense_Mutation | novel | c.471G>C | p.Lys157Asn | p.K157N | Q9Y490 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
TLN1 | SNV | Missense_Mutation | | c.923N>G | p.Tyr308Cys | p.Y308C | Q9Y490 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
TLN1 | SNV | Missense_Mutation | rs770655381 | c.3721C>T | p.Arg1241Trp | p.R1241W | Q9Y490 | protein_coding | deleterious(0) | benign(0.289) | TCGA-A2-A0ET-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
TLN1 | SNV | Missense_Mutation | novel | c.1981G>A | p.Asp661Asn | p.D661N | Q9Y490 | protein_coding | tolerated(0.34) | benign(0.017) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
TLN1 | SNV | Missense_Mutation | | c.1437G>C | p.Gln479His | p.Q479H | Q9Y490 | protein_coding | deleterious(0) | benign(0.087) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TLN1 | SNV | Missense_Mutation | | c.310N>A | p.Asp104Asn | p.D104N | Q9Y490 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TLN1 | SNV | Missense_Mutation | | c.480N>T | p.Lys160Asn | p.K160N | Q9Y490 | protein_coding | deleterious(0.03) | possibly_damaging(0.484) | TCGA-A8-A09E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
TLN1 | SNV | Missense_Mutation | | c.887N>C | p.Val296Ala | p.V296A | Q9Y490 | protein_coding | tolerated(0.09) | benign(0.151) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
TLN1 | SNV | Missense_Mutation | | c.3268G>A | p.Asp1090Asn | p.D1090N | Q9Y490 | protein_coding | tolerated(0.05) | benign(0.025) | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR |
TLN1 | SNV | Missense_Mutation | | c.2862N>C | p.Gln954His | p.Q954H | Q9Y490 | protein_coding | tolerated(0.24) | benign(0.005) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |